Acquired angioedema type 1

Summary

Acquired angioedema type 1 (MONDO:0015056) is a disease. A subtype of acquired angioedema — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acquired angioedema type 1
Mondo ID	MONDO:0015056
Orphanet	100056
UMLS	C5680380
MedGen	1814460
GARD	0019748
Is cancer (heuristic)	no

Also known as: acquired angioneurotic edema type 1 · acquired angioneurotic oedema type 1

Disease family

This is a subtype of acquired angioedema. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria › angioedema › acquired angioedema › acquired angioedema type 1

Related subtypes (4): acquired angioedema type 2, renin-angiotensin-aldosterone system-blocker-induced angioedema, acquired angioedema with C1Inh deficiency, vibratory angioedema

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.